Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

141. Roflumilast (Daxas) for maintenance treatment of severe chronic obstructive lung disease (COPD)

Roflumilast (Daxas) for maintenance treatment of severe chronic obstructive lung disease (COPD) Roflumilast (Daxas®) for maintenance treatment of severe chronic obstructive lung disease (COPD) | Report | National Health Care Institute You are here: Roflumilast (Daxas®) for maintenance treatment of severe chronic obstructive lung disease (COPD) Search within English part of National Health Care Institute Search Roflumilast (Daxas®) for maintenance treatment of severe chronic obstructive lung (...) disease (COPD) Zorginstituut Nederland has carried out an assessment of whether roflumilast (Daxas®) is interchangeable with a drug currently included in the Medicine Reimbursement System (GVS). Registration Roflumilast is registered as an addition to treatment with bronchodilators for the maintenance treatment of severe chronic obstructive lung disease (COPD) associated with chronic bronchitis in adults whose COPD flares up frequently. Roflumilast is available as 500 microgram film-coated tablets

2018 National Health Care Institute (Zorginstituut Nederland)

142. General medicine: Tiotropium could provide benefits in the early stage of COPD, but further studies are needed

established if we must use long-acting bronchodilators in all patients with COPD. This is a critical issue because many patients suffering from COPD do not complain about the classic disturbing symptoms of COPD such as cough, sputum and dyspnoea, despite the present of a mild and even moderate airflow obstruction as measured by spirometry. 2 , 3 Methods A multicentre randomised trial 4 of over 800 Chinese COPD patients with mild to moderate [Global Initiative for Chronic Obstructive Lung Disease (GOLD (...) of COPD, but further studies are needed Mario Cazzola , Paola Rogliani Statistics from Altmetric.com Commentary on : Zhou Y, Zhong NS, Li X, et al . Tiotropium in early-stage chronic obstructive pulmonary disease. N Engl J Med . 2017;377:923–935. Context Although bronchodilators are the first-line maintenance treatment for chronic obstructive pulmonary disease (COPD), we still ignore what their real role is in treating obstructed asymptomatic patients. 1 For this reason it is still not well

2018 Evidence-Based Medicine

143. Trelegy Ellipta - fluticasone furoate umeclidinium vilanterol - Chronic obstructive pulmonary disease (COPD)

. Indications: Chronic obstructive pulmonary disease (COPD) Manufacturer Requested Reimbursement Criteria 1 : For the long-term, once daily, maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, where the following clinical criteria are met: - Moderate to severe COPD as defined by spirometry; and - At risk of exacerbations despite a long-acting bronchodilator (LAMA or LABA); or - Symptomatic or at risk of exacerbations despite a LAMA/LABA (...) Trelegy Ellipta - fluticasone furoate umeclidinium vilanterol - Chronic obstructive pulmonary disease (COPD) fluticasone furoate/umeclidinium/vilanterol | CADTH.ca Find the information you need fluticasone furoate/umeclidinium/vilanterol fluticasone furoate/umeclidinium/vilanterol Last Updated: September 19, 2018 Result type: Reports Project Number: SR0562-000 Product Line: Generic Name: fluticasone furoate umeclidinium vilanterol Brand Name: Trelegy Ellipta Manufacturer: GlaxoSmithKline Inc

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

144. Short-Term Effects of Normocapnic Hyperpnea and Exercise Training in Patients With Chronic Obstructive Pulmonary Disease: A Pilot Study. (Abstract)

Short-Term Effects of Normocapnic Hyperpnea and Exercise Training in Patients With Chronic Obstructive Pulmonary Disease: A Pilot Study. The aim of the study was to evaluate the short-term physiologic effects of respiratory muscle training with normocapnic hyperpnea added to standard exercise training on respiratory muscle endurance/strength and exercise tolerance in patients with chronic obstructive pulmonary disease.The study used a randomized controlled trial. Patients referred (...) training alone, improves respiratory muscle endurance and strength but not exercise tolerance in patients with chronic obstructive pulmonary disease.

2018 American journal of physical medicine & rehabilitation Controlled trial quality: uncertain

145. Randomised controlled trial: Non-invasive positive pressure ventilation should be considered in patients with COPD and persistent hypercapnia at least 2 weeks after resolution of acute respiratory failure

noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. JAMA 2017;317:2177–86. Implications for practice and research Non-invasive positive pressure ventilation (NPPV) should be considered in patients with chronic obstructive pulmonary disease (COPD) with persistent hypercapnia 2–4 weeks after resolution of acute respiratory failure. Timely follow-up after hospitalisation for acute respiratory (...) failure is important. Further trials are needed to confirm the findings and to clarify which patients benefit most, the role of concurrent obstructive sleep apnoeas and optimal ventilator settings of NPPV in stable hypercapnic COPD. Context NPPV improves outcomes and should be standard care in patients with acute hypercapnic respiratory failure, indicated by respiratory acidosis, in COPD. 1 Chronic hypercapnia is … Request Permissions If you wish to reuse any or all of this article please use the link

2018 Evidence-Based Nursing

146. Overview of COPD

Overview of COPD Overview of COPD - Summary of relevant conditions | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Overview of COPD Last reviewed: February 2019 Last updated: June 2018 Introduction Chronic obstructive pulmonary disease (COPD) is a disorder that is usually progressive, characterised by airflow limitation that is not fully reversible. Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med. 2004;350 (...) . 2010;363:1128-1138. http://www.nejm.org/doi/full/10.1056/NEJMoa0909883 http://www.ncbi.nlm.nih.gov/pubmed/20843247?tool=bestpractice.com and may themselves accelerate the progression of COPD. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847-852. http://www.ncbi.nlm.nih.gov/pubmed/12324669?tool=bestpractice.com In addition to the usual therapies used for COPD, antibiotics have

2018 BMJ Best Practice

147. Acute exacerbation of chronic obstructive pulmonary disease

) and/or diarrhoea, including Clostridium difficile -associated diarrhoea (associated with the use of antibiotics). Definition Chronic obstructive pulmonary disease (COPD) is "a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases." Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis (...) , management and prevention of chronic obstructive pulmonary disease. November 2017 [internet publication] http://goldcopd.org/gold-reports/ An exacerbation of COPD may be defined as "an acute worsening of respiratory symptoms that results in additional therapy." Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. November 2017 [internet publication] http://goldcopd.org/gold-reports/ History and exam

2018 BMJ Best Practice

148. COPD

COPD COPD - Symptoms, diagnosis and treatment | BMJ Best Practice   Search  COPD Last reviewed: February 2019 Last updated: November 2018 Summary Progressive disease state characterised by airflow limitation that is not fully reversible. Suspected in patients with a history of smoking, occupational and environmental risk factors, or a personal or family history of chronic lung disease. Presents with progressive shortness of breath, wheeze, cough, and sputum production, including haemoptysis (...) characterised by airflow limitation that is not fully reversible. It encompasses both emphysema and chronic bronchitis. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases. It is primarily caused by cigarette smoking. Although COPD affects the lungs, it also has significant systemic consequences. Exacerbations and comorbidities are important contributors to the overall condition and prognosis in individual patients

2018 BMJ Best Practice

149. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study Full Text available with Trip Pro

Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study Oxidative stress contributes to chronic obstructive pulmonary disease (COPD) exacerbations and antioxidants can decrease exacerbation rates, although we lack data about the effect of such drugs on exacerbation duration.The RESTORE (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine in COPD) study was a prospective randomised, double-blind, placebo-controlled study, enrolling patients aged (...) 40-80 years with Global Initiative for Chronic Obstructive Lung Disease stage II/III. Patients received erdosteine 300 mg twice daily or placebo added to usual COPD therapy for 12 months. The primary outcome was the number of acute exacerbations during the study.In the pre-specified intention-to-treat population of 445 patients (74% male; mean age 64.8 years, forced expiratory volume in 1 s 51.8% predicted) erdosteine reduced the exacerbation rate by 19.4% (0.91 versus 1.13 exacerbations·patient

2018 EvidenceUpdates Controlled trial quality: predicted high

150. Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD Full Text available with Trip Pro

with moderate to very severe airflow limitation and a broad range of COPD symptoms.These post hoc analyses of pooled data investigated whether baseline symptom burden, assessed using the COPD Assessment Test (CAT) score, impacted GFF MDI-associated improvements in lung function, health status, rescue medication use, and exacerbation risk.In 3,699 patients, improvement in FEV1 at week 24 between the GFF MDI and monocomponent MDIs and a placebo MDI was similar in magnitude regardless of baseline CAT score (...) Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD The clinical severity of COPD is currently categorized by symptom burden and exacerbation risk. Previous 24-week phase III trials (NCT01854645 and NCT01854658) that demonstrated better improvement of lung function with glycopyrrolate/formoterol fumarate (GFF) metered dose inhaler (MDI) (an MDI fixed-dose of GFF 18/9.6 μg) over individual monocomponent MDIs included a cross-section of patients

2018 EvidenceUpdates

151. A simple algorithm for the identification of clinical COPD phenotypes Full Text available with Trip Pro

A simple algorithm for the identification of clinical COPD phenotypes This study aimed to identify simple rules for allocating chronic obstructive pulmonary disease (COPD) patients to clinical phenotypes identified by cluster analyses.Data from 2409 COPD patients of French/Belgian COPD cohorts were analysed using cluster analysis resulting in the identification of subgroups, for which clinical relevance was determined by comparing 3-year all-cause mortality. Classification and regression trees (...) (CARTs) were used to develop an algorithm for allocating patients to these subgroups. This algorithm was tested in 3651 patients from the COPD Cohorts Collaborative International Assessment (3CIA) initiative.Cluster analysis identified five subgroups of COPD patients with different clinical characteristics (especially regarding severity of respiratory disease and the presence of cardiovascular comorbidities and diabetes). The CART-based algorithm indicated that the variables relevant for patient

2018 EvidenceUpdates

152. Endobronchial valve insertion to reduce lung volume in emphysema

, a radiologist, a thoracic surgeon and a respiratory nurse. 1.3 Patients selected for treatment should have had pulmonary rehabilitation. 1.4 The procedure should only be done to occlude volumes of the lung where there is no collateral ventilation, by clinicians with specific training in doing the procedure. 2 2 Indications and current treatments Indications and current treatments 2.1 Emphysema is a chronic lung disease in which the walls of the air sacs (alveoli) in the lungs weaken and disintegrate (...) of 3 RCTs (n=482) in the SR. Serious adverse events were reported on 22 occasions in patients treated by umbrella EBV and in 6 patients having SMC in 1 RCT (n=277) included in the SR. The rate of adverse events was statistically significantly higher in patients treated by umbrella EBV than in those having SMC (OR 3.41, 95% CI 1.48 to 7.84) in a meta-analysis of 2 RCTs (n=350) in the SR. 5.3 Chronic obstructive pulmonary disease (COPD) exacerbation episodes were not statistically significantly more

2018 National Institute for Health and Clinical Excellence - Interventional Procedures

153. Managing stable chronic obstructive pulmonary disease — focusing on inhalers

Managing stable chronic obstructive pulmonary disease — focusing on inhalers '); } else { document.write(' '); } ACE | Managing stable chronic obstructive pulmonary disease — focusing on inhalers Search > > Managing stable chronic obstructive pulmonary disease — focusing on inhalers - Managing stable chronic obstructive pulmonary disease — focusing on inhalers Published on 25 September 2018 This Appropriate Care Guide (ACG) outlines the overall recommendations to managing stable COPD

2018 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

154. Diagnosing chronic obstructive pulmonary disease — a systematic approach

Diagnosing chronic obstructive pulmonary disease — a systematic approach '); } else { document.write(' '); } ACE | Diagnosing chronic obstructive pulmonary disease — a systematic approach Search > > Diagnosing chronic obstructive pulmonary disease — a systematic approach - Diagnosing chronic obstructive pulmonary disease — a systematic approach Published on 7 November 2018 This Appropriate Care Guide (ACG) highlights the importance of a thorough assessment of symptoms and risk factors (...) , and to confirm all suspected cases of COPD with spirometry. It incorporates a link to an online list of spirometry services that are open to external referrals. It also includes a supplementary guide on how to interpret a spirometry report. Download the PDF below to access the full ACG. Key Messages 1. Establish smoking history in all patients. In current and ex-smokers, check for respiratory symptoms. 2. Consider COPD in all patients 40 and older with risk factors and symptoms. 3. Confirm all suspected COPD

2018 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

155. LAMA & LAMA/LABA for chronic obstructive pulmonary disease (COPD)

LAMA & LAMA/LABA for chronic obstructive pulmonary disease (COPD) '); } else { document.write(' '); } ACE | LAMA & LAMA/LABA for Chronic obstructive pulmonary disease (COPD) Search > > LAMA & LAMA/LABA for chronic obstructive pulmonary disease (COPD) - LAMA & LAMA/LABA for chronic obstructive pulmonary disease (COPD) Published on 2 July 2018 Guidance Recommendations The Ministry of Health’s Drug Advisory Committee has recommended: Umeclidinium 62.5mcg inhalation powder for the: Maintenance (...) /vilanterol) for maintenance treatment of stable chronic obstructive pulmonary disease (COPD). The Agency for Care Effectiveness conducted the evaluation in consultation with the MOH COPD Expert Working Group comprising senior healthcare professionals from the public healthcare institutions. The use of any LAMA or LAMA/LABA combination for the treatment of asthma was outside the scope of this evaluation. 1.2 By request of the manufacturer, aclidinium (LAMA) and aclidinium/formoterol (LAMA/LABA) were

2018 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

156. Endobronchial valve implantation for emphysema. Update 2018. Decision Support Document 20/ Update 2018.

implantation in selected patients with severe pulmonary emphysema" is more effective but less safe than drug therapy. Item Type: Decision Support Document Keywords: Endobronchial valve implantation, emphysema, lung volume reduction, chronic obstructive pulmonary disease, COPD Subjects: > > > > Language: German Series Name: Decision Support Document 20/ Update 2018 Deposited on: 20 Jul 2018 09:54 Last Modified: 15 Jul 2020 17:57 Repository Staff Only: © Copyright , (...) Endobronchial valve implantation in patients with severe pulmonary emphysema aims to alleviate disease-related symptoms, prevent deterioration of lung function and improve quality of life. The 4th update is based on the results of the Cochrane Review "Bronchoscopic lung volume reduction procedure for chronic obstructive pulmonary disease" (2017): A total of 5 RCTs were evaluated in meta-analyses (703 patients). The available evidence suggests that the investigated intervention "endobronchial valve

2018 Austrian Institute of Health Technology Assessment

157. Natural history of COPD: gaps and opportunities Full Text available with Trip Pro

Natural history of COPD: gaps and opportunities Understanding the natural history of a disease is as important as knowing its cause(s) for effective disease prevention and treatment. Yet, our current understanding of the natural history of chronic obstructive pulmonary disease (COPD) is incomplete and often controversial. This article discusses the current gaps, and hence opportunities for research, in this field. In particular, it discusses the following six specific questions. 1) Is COPD (...) a "single" disease? 2) Is COPD "only" a lung disease? 3) When does COPD begin or what is "early" COPD? 4) How does COPD "progress"? 5) How do we assess disease "severity"? 6) Can COPD be prevented (beyond smoking cessation) or its course be modified once detected?

2017 ERJ open research

158. Role of Breathing Conditions During Exercise Testing on Training Prescription in Chronic Obstructive Pulmonary Disease. (Abstract)

Role of Breathing Conditions During Exercise Testing on Training Prescription in Chronic Obstructive Pulmonary Disease. This study investigated whether different breathing conditions during exercise testing will influence measures of exercise capacity commonly used for training prescription in chronic obstructive pulmonary disease. Twenty-seven patients with chronic obstructive pulmonary disease (forced expiratory volume in 1 sec = 45.6 [9.4]%) performed three maximal exercise tests within 8 (...) or overdosing of exercise in chronic obstructive pulmonary disease. Face masks reduced whereas supplemental oxygen increased patients' exercise capacity. For accurate prescription of exercise in chronic obstructive pulmonary disease, breathing conditions during testing should closely match training conditions.

2017 American journal of physical medicine & rehabilitation Controlled trial quality: uncertain

159. The effectiveness of a nurse-led illness perception intervention in COPD patients: a cluster randomised trial in primary care Full Text available with Trip Pro

The effectiveness of a nurse-led illness perception intervention in COPD patients: a cluster randomised trial in primary care The new COPD-GRIP (Chronic Obstructive Pulmonary Disease - Guidance, Research on Illness Perception) intervention translates evidence regarding illness perceptions and health-related quality of life (HRQoL) into a nurse intervention to guide COPD patients and to improve health outcomes. It describes how to assess and discuss illness perceptions in a structured way (...) in improving the ability to control the disease and health-related behaviours in the short term. Therefore, taking illness perceptions into account when stimulating healthy behaviours in COPD patients should be considered. Further study on influencing the health status and HRQoL is needed.

2017 ERJ open research Controlled trial quality: predicted high

160. The impact of different spirometric definitions on the prevalence of airway obstruction and their association with respiratory symptoms Full Text available with Trip Pro

pulmonary disease (COPD) and examine the association between respiratory symptoms and airway obstruction defined by LLN and fixed ratio. 12 449 twins aged 40-80 years participated in a nationwide survey using the Danish Twin Registry. They completed a questionnaire, underwent clinical examination and recorded prebronchodilator spirometry. Individuals with self-reported asthma were excluded. Clinical COPD was defined by respiratory symptoms together with airway obstruction. 10 329 individuals were (...) The impact of different spirometric definitions on the prevalence of airway obstruction and their association with respiratory symptoms The fixed ratio criterion of forced expiratory volume in 1 s/forced vital capacity <0.70 for diagnosing airway obstruction may overdiagnose the condition, particularly in the elderly, so the lower limit of normal (LLN) is recommended as the most appropriate criterion. Our aim was to compare LLN versus fixed ratio on the prevalence of chronic obstructive

2017 ERJ open research